LncRNA TYMSOS facilitates breast cancer metastasis and immune escape through downregulating ULBP3 DOI Creative Commons
Kejing Zhang,

Xiao‐Lang Tan,

Lei Guo

et al.

iScience, Journal Year: 2023, Volume and Issue: 26(9), P. 107556 - 107556

Published: Aug. 7, 2023

The focus of the study is to examine function TYMSOS in immune escape breast cancer, which most frequently diagnosed malignancy among women globally. Our demonstrated that upregulated was associated with unfavorable prognosis and cancer. promoted malignant phenotypes cancer cells, reduced cytotoxicity NK92 cells on these cells. CBX3 a downstream effector TYMSOS-induced Mechanistic studies showed facilitated CBX3-mediated transcriptional repression ULBP3, it also SYVN1-mediated ubiquitin-proteasomal degradation ULBP3. cell growth, metastasis, via CBX3/ULBP3 or SYVN1/ULBP3 axis. vivo further silencing repressed tumor growth boosted NK cytotoxicity. In sum, metastasis

Language: Английский

The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer DOI Open Access
Cristian Arriaga-Canon, Laura Contreras‐Espinosa, Sergio Aguilar-Villanueva

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(8), P. 7426 - 7426

Published: April 18, 2023

Given their tumor-specific and stage-specific gene expression, long non-coding RNAs (lncRNAs) have demonstrated to be potential molecular biomarkers for diagnosis, prognosis, treatment response. Particularly, the lncRNAs DSCAM-AS1 GATA3-AS1 serve as examples of this because high subtype-specific expression profile in luminal B-like breast cancer. This makes them candidates use clinical practice. However, lncRNA studies cancer are limited sample size restricted determination biological function, which represents an obstacle its inclusion utility. Nevertheless, due specificity among diseases, such cancer, stability body fluids, promising that could improve reliability, sensitivity, techniques used diagnosis. The development lncRNA-based diagnostics therapeutics will useful routine medical practice patient management quality life.

Language: Английский

Citations

38
STAT3 signaling in prostate cancer progression and therapy resistance: An oncogenic pathway with diverse functions DOI Creative Commons
Mehrdokht Sadrkhanloo, Mahshid Deldar Abad Paskeh, Mehrdad Hashemi

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 158, P. 114168 - 114168

Published: Jan. 3, 2023

The categorization of cancers demonstrates that prostate cancer is the most common malignancy in men and it causes high death annually. Prostate patients are diagnosed mainly via biomarkers such as PSA test show poor prognosis. cells rapidly diffuse into different parts body their metastasis also a reason for death. Current therapies include chemotherapy, surgery radiotherapy well targeted therapy. progression regulated by factors STAT3 signaling among them. Growth cytokines IL-6 can induce shows carcinogenic impact. Activation occurs promotes malignant behavior tumor cells. Induction increases glycolysis proliferation prevents apoptosis. Furthermore, induces EMT mechanism increasing metastasis. stimulates drug resistance limitation current works lack experiment related to role radio-resistance tumor. Calcitriol, capsazepine β-elemonic compounds capable targeting its inhibition In addition natural products, small molecules have been developed

Language: Английский

Citations

28
Nanomaterials‐Based Targeting of Long Non‐Coding RNAs in Cancer: A Cutting‐Edge Review of Current Trends DOI
Fatemeh Davodabadi, Bahareh Farasati Far, Saman Sargazi

et al.

ChemMedChem, Journal Year: 2024, Volume and Issue: 19(8)

Published: Jan. 24, 2024

This review article spotlights the burgeoning potential of using nanotherapeutic strategies to target long non-coding RNAs (lncRNAs) in cancer cells. updated discourse underlines prominent role lncRNAs instigating cancer, facilitating its progression, and metastasis, validating lncRNAs' for being effective diagnostic biomarkers therapeutic targets. The manuscript offers an in-depth examination different presently employed modulate lncRNA expression function purposes. Among these strategies, Antisense Oligonucleotides (ASOs), RNA interference (RNAi) technologies, innovative clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing tools garner noteworthy mention. A significant section is dedicated nanocarriers their crucial drug delivery. These nanocarriers' efficiency targeting varied types cancers elaborated upon, importance targeted therapy. culminates by reaffirming promising prospects enhance accuracy diagnosis improve treatment efficacy. Consequently, new paths are opened more research innovation employing approaches against Thus, this comprehensive serves as a valuable resource that underscores vital various nano-strategies them treatment. Future should also focus on unraveling complex regulatory networks involving identifying fundamental functional interactions refine cancer.

Language: Английский

Citations

11
Role of ferroptosis and ferroptosis-related long non'coding RNA in breast cancer DOI Creative Commons
Shasha Xiang, Wen Yan,

Xing Ren

et al.

Cellular & Molecular Biology Letters, Journal Year: 2024, Volume and Issue: 29(1)

Published: March 26, 2024

Abstract Ferroptosis, a therapeutic strategy for tumours, is regulated cell death characterised by the increased accumulation of iron-dependent lipid peroxides (LPO). Tumour-associated long non-coding RNAs (lncRNAs), when combined with traditional anti-cancer medicines or radiotherapy, can improve efficacy and decrease mortality in cancer. Investigating role ferroptosis-related lncRNAs may help strategise new options breast cancer (BC). Herein, we briefly discuss genes pathways ferroptosis involved iron reactive oxygen species (ROS) metabolism, including X C − /GSH/GPX4 system, ACSL4/LPCAT3/15-LOX FSP1/CoQ10/NAD(P)H pathways, investigate correlation between LncRNA BC to determine possible biomarkers related ferroptosis.

Language: Английский

Citations

10
The expression of the lncRNAs USP30-AS1, ELFN1-AS1, GAS8-AS1, and SNHG11 in breast cancer samples from Iranian patients from 2014 to 2019: a cross-sectional study DOI Creative Commons
Ghazal Orak, Zahra Orak Chahartangi, Zahra Nazeri

et al.

BMC Research Notes, Journal Year: 2025, Volume and Issue: 18(1)

Published: Jan. 5, 2025

Breast cancer is a widely prevalent and life-threatening malignancy that affects women worldwide. The identification of novel molecular markers associated with tumor progression highly important for enhancing early detection, tailoring treatment approaches, monitoring therapeutic outcomes. In this study, we investigated the expression patterns four long noncoding RNAs (lncRNAs): USP30 antisense RNA1 (USP30-AS1), ELFN1 (ELFN1-AS1), GAS8 (GAS8-AS1), small nucleolar RNA host gene 11 (SNHG11). breast specimens, USP30-AS1 GAS8-AS1 was decreased, whereas ELFN1-AS1 SNHG11 increased in tissues compared adjacent noncancer tissues. Decreased levels were smaller size, lower grade stage, absence lymphatic vascular invasion. Lower positive estrogen progestin receptor status. Elevated lacked P53 mutation. These changes suggest their promise as biomarkers distinguishing between cancerous noncancerous

Language: Английский

Citations

1
Long non-coding RNA involved in the carcinogenesis of human female cancer - a comprehensive review DOI Creative Commons
Nazia Afroze, Madhumitha Kedhari Sundaram,

Shafiul Haque

et al.

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 6, 2025

Recent years have seen an increase in our understanding of lncRNA and their role various disease states. molecules been shown to contribute carcinogenesis influence the cancer hallmarks signalling pathways. It is pertinent understand specific contributions mechanisms action these cancers. This review provides overview entities that regulate gynaecological cancers, namely, cervical, breast, ovarian uterine The curates a list key players effect on cellular processes. show immense potential be used as diagnostic prognostic indicators therapeutic strategies. Several phytochemicals, small molecules, RNA-based regulators, oligos gene editing tools promise strategy. While this highlights promising developments field, it also underscores necessity for further research delineate complex lncRNAs cancer.

Language: Английский

Citations

1
MAGI2-AS3 and miR-374b-5p as Putative Regulators of Multiple Sclerosis via Modulating the PTEN/AKT/IRF-3/IFN-β Axis: New Clinical Insights DOI
Mona A. Kortam, Nourhan Elfar, Olfat Shaker

et al.

ACS Chemical Neuroscience, Journal Year: 2023, Volume and Issue: 14(6), P. 1107 - 1118

Published: March 6, 2023

Multiple sclerosis (MS) is a chronic disease and one of the leading causes disability in young adults. The current study aims to investigate pathogenesis MS via studying regulatory role novel lncRNA MAGI2-AS3 miR-374b-5p their downstream targets PTEN/AKT/IRF-3/IFN-β relationship this pathway with severity. Moreover, it assess MAGI2-AS3/miR-374b-5p as diagnostic and/or prognostic biomarkers for MS. Overall, 150 contributors were recruited: 100 patients 50 healthy volunteers. Gene expression MAGI2-AS3, miR-374b-5p, PTEN, AKT, IRF-3 assessed using RT-qPCR, IFN-β was measured by ELISA. Compared control group, serum PTEN downregulated patients, whereas PI3K, IRF-3, upregulated patients. Furthermore, downregulated, while an expanded status scale (EDSS) ≥3.5, compared EDSS <3.5. Receiver-operating-characteristic curve analysis revealed that can be used diagnosis Remarkably, multivariate logistic AKT act independent variables directly correlated inversely EDSS. Regarding positively In conclusion, showed first time crosstalk between could affect AKT/IRF3/IFN-β axis Interestingly, genetic noninvasive

Language: Английский

Citations

20
Long Non-Coding RNAs, Cell Cycle, and Human Breast Cancer DOI
Qinan Yin,

Haodi Ma,

Gayan Bamunuarachchi

et al.

Human Gene Therapy, Journal Year: 2023, Volume and Issue: 34(11-12), P. 481 - 494

Published: May 27, 2023

The long non-coding RNAs (lncRNAs) constitute an important class of the human transcriptome. discovery lncRNAs provided one many unexpected results post-genomic era and uncovered a huge number previously ignored transcriptional events. In recent years, are known to be linked with diseases, particular focus on cancer. Growing evidence has indicated that dysregulation in breast cancer (BC) is strongly associated occurrence, development, progress. Increasing numbers have been found interact cell cycle progression tumorigenesis BC. can exert their effect as tumor suppressor or oncogene regulate development through direct indirect regulation cancer-related modulators signaling pathways. What more, excellent candidates for promising therapeutic targets BC due features high tissue cell-type specific expression. However, underlying mechanisms still remain largely undefined. Here, we concisely summarize sort out current understanding research progress relationships roles lncRNA regulating cycle. We also aberrant expression BC, potential improve therapy discussed. Together, considered exciting whose altered impede progression.

Language: Английский

Citations

18
Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer DOI

Yue Pan,

Qianqian Zhang, Hongwei Zhang

et al.

Functional & Integrative Genomics, Journal Year: 2023, Volume and Issue: 23(1)

Published: Jan. 14, 2023

Language: Английский

Citations

17
Long Noncoding RNA VLDLR-AS1 Levels in Serum Correlate with Combat-Related Chronic Mild Traumatic Brain Injury and Depression Symptoms in US Veterans DOI Open Access
Rekha Patel, Meredith Krause‐Hauch, Kimbra Kenney

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(3), P. 1473 - 1473

Published: Jan. 25, 2024

More than 75% of traumatic brain injuries (TBIs) are mild (mTBI) and military service members often experience repeated combat-related mTBI. The chronic comorbidities concomitant with repetitive mTBI (rmTBI) include depression, post-traumatic stress disorder or neurological dysfunction. This study sought to determine a long noncoding RNA (lncRNA) expression signature in serum samples that correlated rmTBI years after the incidences. Serum were obtained from Long-Term Impact Military-Relevant Brain-Injury Consortium Chronic Effects Neurotrauma (LIMBIC CENC) repository, participants unexposed TBI who had rmTBI. Four lncRNAs identified as consistently present all samples, detected via droplet digital PCR packaged exosomes enriched for CNS origin. results, using qPCR, demonstrated lncRNA VLDLR-AS1 levels significantly lower among individuals compared those no lifetime TBI. ROC analysis determined an AUC 0.74 (95% CI: 0.6124 0.8741; p = 0.0012). optimal cutoff was ≤153.8 ng. A secondary clinical data LIMBIC CENC conducted evaluate psychological symptom burden, results show MALAT1 symptoms depression. In conclusion, may serve blood biomarker identifying depression patients.

Language: Английский

Citations

7